Shenqing Zhang

Shenqing Zhang

Auto-generated profile, based on publicly available information

Shenqing Zhang

Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SZShenqing Zhang
Shenqing Zhang
HXHuaijiang Xiang
Huaijiang Xiang
YTYouqi Tao
Youqi Tao
JLJuan Li
Juan Li
SZShuyi Zeng
Shuyi Zeng
CLCong Liu
Cong Liu
The amyloid fibrils of α-synuclein (α-syn) are crucial in the pathology of Parkinson's disease (PD), with the intrinsically disordered region (IDR) of its C-terminal playing a key role in interacting with receptors like LAG3 and RAGE, facilitating pathological neuronal spread and inflammation. In this study, we identified Givinostat (GS) as an effective inhibitor that disrupts the interaction of α-syn fibrils with receptors such as LAG3 and RAGE through high-throughput screening. By exploring the structure-activity relationship and optimizing GS, we developed several lead compounds, including GSD-16-24. Utilizing solution-state and solid-state NMR, along with cryo-EM techniques, we demonstrated that GSD-16-24 binds directly to the C-terminal IDR of α-syn monomer and fibril, preventing the fibril from binding to the receptors. Furthermore, GSD-16-24 significantly inhibits the association of α-syn fibrils with membrane receptors, thereby reducing neuronal propagation and pro-inflammatory effects of α-syn fibrils. Our findings introduce a novel approach to mitigate the pathological effects of α-syn fibrils by targeting their IDR with small molecules, offering potential leads for the development of clinical drugs to treat PD.

1 July 2023 in Fundamental Research
Verified
Journal Article
Open access
SZShenqing Zhang
Shenqing Zhang
HDHui Dong
Hui Dong
JBJiang Bian
Jiang Bian
DLDan Li
Dan Li
CLCong Liu
Cong Liu
Abnormal aggregation and accumulation of pathological amyloid proteins such as amyloid-β, Tau, and α-synuclein play key pathological roles and serve as histological hallmarks in different neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD). In addition, various post-translational modifications (PTMs) have been identified on pathological amyloid proteins and are subjected to change during disease progression. Given the central role of amyloid proteins in NDs, tremendous efforts have been made to develop amyloid-targeting strategies for clinical diagnosis and molecular classification of NDs. In this review, we summarize two major strategies for targeting amyloid aggregates, with a focus on the trials in AD diagnosis. The first strategy is a positron emission tomography (PET) scan of protein aggregation in the brain. We mainly focus on introducing the development of small-molecule PET tracers for specifically recognizing pathological amyloid fibrils. The second strategy is the detection of PTM biomarkers on amyloid proteins in cerebrospinal fluid and plasma. We discuss the pathological roles of different PTMs in diseases and how we can use the PTM profile of amyloid proteins for clinical diagnosis. Finally, we point out the potential technical challenges of these two strategies, and outline other potential strategies, as well as a combination of multiple strategies, for molecular diagnosis of NDs.

11 October 2024 in Science Advances
Verified
Journal Article
Open access
DMDong-Fei Ma
Dong-Fei Ma
SZShenqing Zhang
Shenqing Zhang
SXSi-Yao Xu
Si-Yao Xu
ZHZi Huang
Zi Huang
YTYuanxiao Tao
Yuanxiao Tao
YLYing Lu
Ying Lu
α-Synuclein (α-syn), a crucial molecule in Parkinson’s disease (PD), is known for its interaction with lipid membranes, which facilitates vesicle trafficking and modulates its pathological aggregation. Deciphering the complexity of the membrane-binding behavior of α-syn is crucial to understand its functions and the pathology of PD. Here, we used single-molecule imaging to show that α-syn forms multimers on lipid membranes with huge intermultimer distances. The multimers are characterized by self-limiting growth, manifesting in concentration-dependent exchanges of monomers, which are fast at micromolar concentrations and almost stop at nanomolar concentrations. We further uncovered movement patterns of α-syn’s occasional trapping on membranes, which may be attributed to sparse lipid packing defects. Mutations such as E46K and E35K may disrupt the limit on the growth, resulting in larger multimers and accelerated amyloid fibril formation. This work emphasizes sophisticated regulation of α-syn multimerization on membranes as a critical underlying factor in the PD pathology.

1 August 2008
Verified
Conference Paper
Closed access
XZXiaosong Zhao
Xiaosong Zhao
ZHZhen He
Zhen He
FGFangfang Gui
Fangfang Gui
SZShenqing Zhang
Shenqing Zhang
Combined the methods and tools of six sigma and the characteristics of software enterprises, continuous quality improvement is implemented throughout the software development process for high-quality software product. Based on the DMAIC of six sigma improvement, the model of software engineering process is established, in which the design of six sigma is applied to building the model for demand engineering process. The defects are prevented from the design source. The tools and methods of six sigma are applied to discovery and eliminate the defects of software process, which can ensure final quality of the software product. Finally, the case analysis is implemented; the results show that this method is feasible.